Pharmacokinetics of flutamide in patients with renal insufficiency

British Journal of Clinical Pharmacology

Volumn 47, Issue 1, 1999, Pages 43-47

  Anjum, S ^a   Swan, S K ^a   Lambrecht, L J ^a   Radwanski, E ^b   Cutler, D L ^b   Affrime, M B ^b   Halstenson, C E ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Flutamide; Pharmacokinetics; Renal failure

Indexed keywords

ANTIANDROGEN; CREATININE; FLUTAMIDE; HYDROXYFLUTAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISPOSITION; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANDROGEN ANTAGONISTS; AREA UNDER CURVE; FLUTAMIDE; HALF-LIFE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0032895995     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00831.x     Document Type: Article

References (5)

1. 1 Neri RO, Koziol P, Kung T. SCH 15423 (α, α, α-trifluoro-2-methyl-4′-nitro-M-lactotoluidide), a potent anti androgen. Endocrinology 1975; 96 (Suppl): 298-298.
2. 2 Peets E, Henson F, Neri R. Effect of non-steroidal anti androgen SCH 15423 (α, α, α-trifluoro-2-methyl-4′-nitro-M-lactotoluidide) on androgen disposition in rats. Endocrinology 1975; 96 (Suppl): 306-306.
3. 3 Schulz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 1988; 34: 633-636.
4. 4 Neri R. Pharmacology and pharmacokinetics of flutamide. Urology 1989; 34: 19-21.
5. 5 Radwanski E, Perentesis G, Symchowicz S, Zampaglione N. Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J Clin Pharmacol 1989; 29: 554-558.